Los Angeles, CA, Dec. 9, 2014 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI") will present at the
inaugural equities.com Small-Cap Stars Conference on Thursday,
December 18th at 12:45 PM ET. The event is being held in
New York, NY at the NASDAQ MarketSite in Times Square.
Jeff Baxter, VBI's President and CEO, will provide an overview
of the Company's business during his live presentation and will be
available to participate in one-on-one meetings with investors who
are registered to attend the event.
The equities.com Small-Cap Stars Conference features an
exclusive group of hand-selected emerging growth and under-covered
small cap companies. For additional information, visit: http://www.equitiesevents.com/
Event: equities.com Small-Cap Stars
Conference
Date: Thursday, December 18th,
2014
Time: 12:45 PM ET
Location: NASDAQ MarketSite in Times Square,
New York, NY
About equities.com, Inc.
equities.com is an online financial
publication and social community for self-directed investors,
public and private companies, market experts, and professional
service providers across the global capital markets. To learn more,
visit: http://www.equities.com
About VBI Vaccines Inc.
VBI Vaccines Inc. ("VBI") is a biopharmaceutical company
developing novel technologies that seek to expand vaccine
protection in large underserved markets. VBI's eVLP vaccine
platform allows for the design of enveloped ("e") virus-like
particle ("VLP") vaccines that closely mimic the target virus.
VBI's lead eVLP asset is a prophylactic Cytomegalovirus ("CMV")
vaccine; VBI has initiated work for GMP manufacturing of its CMV
candidate for use in formal preclinical and Phase I trials. VBI's
second platform is a thermostable technology that enables the
development of vaccines and biologics that can withstand storage or
shipment at constantly fluctuating temperatures. VBI has completed
proof of concept thermostability studies on a number of vaccine and
biologic targets. VBI is headquartered in Cambridge, MA with
research facilities in Ottawa, Canada.
Website Home: http://www.vbivaccines.com
News and Insights: http://www.vbivaccines.com/wire/
Investors: http://ir.vbivaccines.com/
Forward-Looking Statement Disclosure
This press release contains certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended, including statements regarding the efficacy of
potential products, the timelines for bringing such products to
market, and the availability of funding sources for continued
development of such products. Forward-looking statements are based
on management's estimates, assumptions, and projections, and are
subject to uncertainties, many of which are beyond the control of
VBI. Actual results may differ materially from those anticipated in
any forward-looking statement. Factors that may cause such
differences include the risks that potential products that appear
promising to VBI cannot be shown to be efficacious or safe in
subsequent preclinical or clinical trials, VBI will not obtain
appropriate or necessary governmental approvals to market these or
other potential products, VBI may not be able to obtain anticipated
funding for its development projects or other needed funding, and
VBI may not be able to secure or enforce adequate legal protection,
including patent protection, for its products. All forward-looking
statements included in this press release are made only as of the
date of this press release, and VBI does not undertake any
obligation to publicly update or correct any forward-looking
statements to reflect events or circumstances that subsequently
occur or of which we hereafter become aware.
More detailed information about VBI and risk factors that may
affect the realization of forward-looking statements, including the
forward-looking statements in this press release, is set forth in
VBI's filings with the Securities and Exchange Commission (the
"Commission"). VBI urges investors and security holders to read
those documents free of charge at the Commission's Web site
at http://www.sec.gov.
Interested parties may also obtain those documents free of
charge from VBI. Forward-looking statements speak only as to the
date they are made, and except for any obligation under the U.S.
federal securities laws, VBI undertakes no obligation to publicly
update any forward-looking statement as a result of new
information, future events or otherwise.
CONTACT: VBI Contact
Jeff Baxter, President and CEO
Phone: (617) 830-3031 x125
Email: ir@vbivaccines.com
VBI Investor Contacts
Robert B. Prag, President
The Del Mar Consulting Group, Inc.
Phone: (858) 361-1786
Email: bprag@delmarconsulting.com
Scott Wilfong, President
Alex Partners, LLC
Phone: (425) 242-0891
Email: scott@alexpartnersllc.com
